Targeting Toll-Like Receptor 9 with CpG Oligodeoxynucleotides Enhances Anti-Tumor Responses of Peripheral Blood Mononuclear Cells from Human Lung Cancer Patients

REFERENCES

• Al-Hamdan N., Al-Jarallah M., Al-Jarallah M., Ravichandran K., Al-Sayyad J., Al-Lawati J., Khazal Z., Al-Khateeb F., Abdulwahab A., Al-Mulla A., Al-Asfour A., Bazarbashi S. The incidence of lung cancer in the Gulf Cooperation Council countries. Ann. Saudi. Med. 2006; 26: 433–438
   PubMed Web of Science ®Google Scholar
• Bhurgri Y., Bhurgri A., Usman A., Sheikh N., Faridi N., Malik J., Ahmed R., Kayani N., Pervez S., Hasan S. H. Patho-epidemiology of lung cancer in Karachi. Asian Pac. J. Cancer Prev. 2006; 7(1)60–64
   PubMedGoogle Scholar
• Ishikawa H., Nakayama Y., Kitamoto Y., Nonaka T., Kawamura H., Shirai K., Sakurai H., Hayakawa K., Niibe H., Nakano T. Effect of histologic type on recurrence pattern in radiation therapy for medically inoperable patients with stage I non-small-cell lung cancer. Lung 2006; 184(6)347–353
   PubMed Web of Science ®Google Scholar
• Paull D. E., Thomas M. L., Meade G. E., Updyke G. M., Arocho M. A., Chin H. W., Adebonojo S. A., Little A. G. Determinants of quality of life in patients following pulmonary resection for lung cancer. Am. J. Surg. 2006; 192(5)565–571
   PubMed Web of Science ®Google Scholar
• Cross D., Burmester J. K. Gene therapy for cancer treatment: past, present and future. Clin. Med. Res. 2006; 4(3)218–227
   PubMedGoogle Scholar
• Ramirez B. S., Pestana E. S., Hidalgo G. G., Garcia T. H., Rodriguez R. P., Ullrich A., Fernandez L. E. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int. J. Cancer. 2006; 119(9)2190–2199
   PubMed Web of Science ®Google Scholar
• Crosti M., Longhi R., Consogno G., Melloni G., Zannini P., Protti M. P. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J. Immunol. 2006; 176(8)5093–5099
   PubMed Web of Science ®Google Scholar
• Saito T., Gale M. Jr. Principles of intracellular viral recognition. Curr. Opin. Immunol. 2007; 19(1)17–23
   PubMed Web of Science ®Google Scholar
• Werling D., Jungi T. W. Toll-like receptors linking innate and adaptive immune response. Vet. Immunol. Immunopathol. 2003; 91(1)1–12
   PubMed Web of Science ®Google Scholar
• Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., Wader T., Tluk S., Liu M., Davis H. L., Krieg A. M. Eur. J. Immunol. 2004; 34(1)251–262
   Google Scholar
• O'Keeffe M., Grumont R. J., Hochrein H., Fuchsberger M., Gugasyan R., Vremec D., Shortman K., Gerondakis S. Distinct roles for the NF-kappaB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals. Blood 2005; 106(10)3457–3464
   PubMed Web of Science ®Google Scholar
• Kraft A. R., Krux F., Schimmer S., Ohlen C., Greenberg P. D., Dittmer U. CpG Oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection. Blood 2007; 109(7)2982–2984
   PubMed Web of Science ®Google Scholar
• Chaudhry U. I., Kingham T. P., Plitas G., Katz S. C., Raab J. R., DeMatteo R. P. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res. 2006; 66(21)10497–10504
   PubMed Web of Science ®Google Scholar
• Krieg A. M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006; 5(6)471–484
   PubMed Web of Science ®Google Scholar
• Giannetti P., Facciabene A., La M. N., Aurisicchio L. Individual mouse analysis of the cellular immune response to tumor antigens in peripheral blood by intracellular staining for cytokines. J. Immunol. Methods. 2006; 316(1–2)84–96
   PubMed Web of Science ®Google Scholar
• Avigan D., Vasir B., Gong J., Borges V., Wu Z., Uhl L., Atkins M., Mier J., McDermott D., Smith T., Giallambardo N., Stone C., Schadt K., Dolgoff J., Tetreault J. C., Villarroel M., Kufe D. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 2004; 10(14)4699–4708
   PubMed Web of Science ®Google Scholar
• Lecoeur H., Fevrier M., Garcia S., Riviere Y., Gougeon M. L. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J. Immunol. Methods. 2001; 253(1–2)177–187
   PubMed Web of Science ®Google Scholar
• Lubin I., Segall H., Marcus H., David M., Kulova L., Steinitz M., Erlich P., Gan J., Reisner Y. Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood 1994; 83(8)2368–2381
   PubMed Web of Science ®Google Scholar
• Gazzinelli R. T., Denkers E. Y. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat. Rev. Immunol. 2006; 6(12)895–906
   PubMed Web of Science ®Google Scholar
• Creagh E. M., O'Neill L. A. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. 2006; 27(8)352–357
   PubMed Web of Science ®Google Scholar
• Nemazee D., Gavin A., Hoebe K., Beutler B. Immunology: Toll-like receptors and antibody responses. Nature 2006; 441(7091)4
   PubMed Web of Science ®Google Scholar
• Watts C., Zaru R., Prescott A. R., Wallin R. P., West M. A. Proximal effects of Toll-like receptor activation in dendritic cells. Curr. Opin. Immunol. 2007; 19(1)73–78
   PubMed Web of Science ®Google Scholar
• Boonstra A., Rajsbaum R., Holman M., Marques R., Asselin-Paturel C., Pereira J. P., Bates E. E., Akira S., Vieira P., Liu Y. J., Trinchieri G., O'Garra A. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J. Immunol. 2006; 177(11)7551–7558
   PubMed Web of Science ®Google Scholar
• Yarovinsky F., Zhang D., Andersen J. F., Bannenberg G. L., Serhan C. N., Hayden M. S., Hieny S., Sutterwala F. S., Flavell R. A., Ghosh S., Sher A. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005; 308(5728)1626–1629
   PubMed Web of Science ®Google Scholar
• Dasari P., Nicholson I. C., Hodge G., Dandie G. W., Zola H. Expression of toll-like receptors on B lymphocytes. Cell Immunol. 2005; 236(1–2)140–145
   PubMed Web of Science ®Google Scholar
• Rothenfusser S., Tuma E., Wagner M., Endres S., Hartmann G. Recent advances in immunostimulatory CpG oligonucleotides. Curr Opin Mol Ther. 2003; 5(2)98–106
   PubMed Web of Science ®Google Scholar
• Gursel M., Verthelyi D., Gursel I., Ishii K. J., Klinman D. M. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J. Leukoc. Biol. 2002; 71(5)813–820
   PubMed Web of Science ®Google Scholar
• Verthelyi D., Ishii K. J., Gursel M., Takeshita F., Klinman D. M. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J. Immunol. 2001; 166(4)2372–2377
   PubMed Web of Science ®Google Scholar
• Krug A., Rothenfusser S., Selinger S., Bock C., Kerkmann M., Battiany J., Sarris A., Giese T., Speiser D., Endres S., Hartmann G. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J. Immunol. 2003; 170(7)3468–3477
   PubMed Web of Science ®Google Scholar
• Kilinc M. O., Aulakh K. S., Nair R. E., Jones S. A., Alard P., Kosiewicz M M., Egilmez N K. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J. Immunol. 2006; 177(10)6962–6973
   PubMed Web of Science ®Google Scholar
• Kaim U., Moritz A., Failing K., Baumgartner W. The regression of a canine Langerhans cell tumour is associated with increased expression of IL-2, TNF-alpha, IFN-gamma and iNOS mRNA. Immunology 2006; 118(4)472–482
   PubMed Web of Science ®Google Scholar
• Bao M., Zhang Y., Wan M., Dai L., Hu X., Wu X., Wang L., Deng P., Wang J., Chen J., Liu Y., Yu Y., Wang L. Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide. Clin Immunol. 2006; 118(2–3)180–187
   PubMed Web of Science ®Google Scholar
• Li N., Fan X. G., Chen Z. H., Huang Y., Quan J., Liu Z. B. Anti-HBV effects of CpG oligodeoxynucleotide-activated peripheral blood mononuclear cells from patients with chronic hepatitis B. APMIS 2005; 113(10)647–654
   PubMed Web of Science ®Google Scholar
• Krug A., Rothenfusser S., Hornung V., Jahrsdorfer B., Blackwell S., Ballas Z. K., Endres S., Krieg A. M., Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 2001; 31(7)2154–2163
   PubMed Web of Science ®Google Scholar
• Sun S., Zhang X., Tough D. F., Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 1998; 188(12)2335–2342
   PubMed Web of Science ®Google Scholar
• Kranzer K., Bauer M., Lipford G B., Heeg K., Wagner H., Lang R. CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology 2000; 99(2)170–178
   PubMed Web of Science ®Google Scholar
• Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol. 2007; 19(1)39–45
   PubMed Web of Science ®Google Scholar